A new skin cancer therapy cuts risk of death by half
A phase II clinical trial for a skin cancer vaccine has delivered very promising results. Developed by Moderna, the vaccine is designed to work alongside another immunotherapy treatment called KEYTRUDA, which also helps the body fight cancer. KEYTRUDA is owned by Merck (also known as MSD), and the ongoing clinical trial is a collaboration between…
